bromocriptine and pergolide
bromocriptine has been researched along with pergolide in 173 studies
Research
Studies (173)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 59 (34.10) | 18.7374 |
1990's | 56 (32.37) | 18.2507 |
2000's | 48 (27.75) | 29.6817 |
2010's | 6 (3.47) | 24.3611 |
2020's | 4 (2.31) | 2.80 |
Authors
Authors | Studies |
---|---|
George, SR; Guan, HC; Laurier, LG; Ng, G; Niznik, HB; O'Dowd, BF; Seeman, P; Sunahara, RK; Torchia, J; Van Tol, HH | 1 |
Anderson, PS; Baldwin, JJ; Clineschmidt, BV; Hirshfield, JM; Jones, JH; Lundell, GF; Martin, GE; McClure, DE; Randall, WC; Williams, M | 1 |
Anderson, PS; Baldwin, JJ; Clineschmidt, BV; Hirshfield, JM; Jones, JH; Lumma, PK; Lundell, GF; Martin, GE; McClure, DE; Randall, WC; Remy, DC; Williams, M | 1 |
Hamblin, MW; Jose, PA; Metcalf, MA; Monsma, FJ; Shen, Y; Sibley, DR | 1 |
Dolak, LA; Duncan, JN; Heier, RF; Hyslop, DK; Lipton, MF; Martin, IJ; Mauragis, MA; Moon, MW; Nichols, NF; Piercey, MF; Schreur, PJ; Smith, MW | 1 |
Brusniak, MY; DuRand, CJ; Huang, WH; Neve, KA; Pearlman, RS; Teeter, MM; Wiens, BL; Wilcox, DM; Wilcox, RE | 1 |
Audinot, V; Boutin, JA; Cussac, D; Maiofiss, L; Millan, MJ; Newman-Tancredi, A | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Christoffersen, CT; Jensen, AA; Kehler, J; Krogsgaard-Larsen, N; Schrøder, TJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Oliveri, V | 1 |
Diederich, NJ; Goetz, CG | 1 |
Helton, DR; Modlin, DL; Williams, PD | 1 |
Pawlikowski, M; Pisarek, H; Stepien, H | 1 |
Berezin, M; Findler, G; Gutman, I; Horowitz, A; Tadmor, R | 1 |
Colbert, W; Owen, N; Turk, J; Williams, P | 1 |
Pisarek, H; Stepien, H | 1 |
Ahlskog, JE; Carmichael, SW; Kelly, PJ; Nelson, A; Okazaki, H; Richelson, E; Stoddard, SL; Tyce, GM; van Heerden, JA | 1 |
Kruk, ZL; Millar, J; Stamford, JA | 1 |
Demichel, P; Moran, A; Roquebert, J; Sauvage, MF | 1 |
Philosophe, R; Seibel, MM | 1 |
Jacobs, MB; Varon, J | 1 |
Ogawa, N | 1 |
Davis, A; Jenner, P; Marsden, CD | 1 |
Goetz, CG | 1 |
Lamberts, SW; Quik, RF | 1 |
Cooper, P; Donahue, B; Lee, C; Newall, J; Persky, M; Rush, S | 1 |
Bemis, KG; Peters, SC; Shannon, HE | 1 |
Avidan, D; Baron, E; Berezin, M | 1 |
Alaoui, K; Morán, A; Roquebert, J | 1 |
Rinne, UK | 2 |
Arnold, WS; Touchet, N; Trugman, JM; Wooten, GF | 1 |
Carroll, VS; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 1 |
Chiodini, PG; Dallabonzana, D; Liuzzi, A; Oppizzi, G; Verde, GG | 1 |
Jenner, P; Marsden, CD | 1 |
Bernstein, J; Buckman, MT; Mattox, JH | 1 |
Boyce, S; Jenner, P; Marsden, CD | 1 |
Corenblum, B | 1 |
Kletzky, OA; Shangold, GA | 1 |
Borenstein, R; Kletzky, OA; Mileikowsky, GN | 1 |
Libertun, C; Lux, VA; Ramírez, MI | 1 |
D'Angelo, L; Fernández, M; Hawkins, M; Jantos, H; Monti, JM | 1 |
Svensson, L | 1 |
Althoff, PH; Fassbinder, W; Haak, T; Jungmann, E; Schöffling, K | 1 |
Factor, SA; Sanchez-Ramos, JR; Weiner, WJ | 1 |
Crosignani, PG; Ferrari, C | 1 |
Klawans, HL; Paleologos, N | 1 |
Ahmed, SR; Shalet, SM | 1 |
Bernstein, J; Buckman, MT; Kellner, R; Mattox, JH; Pathak, D | 1 |
Boyce, S; De Ceballos, ML; Jenner, P; Marsden, CD | 1 |
Casey, DE | 1 |
Jankovic, J | 1 |
Goldstein, M; Lieberman, AN | 1 |
Pepperell, RJ | 1 |
Agid, Y; Dubois, B | 1 |
Horvath, E; Kovacs, KT; Laws, ER; Randall, RV; Scheithauer, BW; Whitaker, MD | 1 |
Glantz, RH; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
Adams, CB; Besser, GM; Charlesworth, M; Doniach, I; Grossman, A; Ross, R; Wass, JA | 1 |
Mattox, JH | 1 |
Burton, K; Calne, DB | 1 |
Dhahir, P; Lemberger, L; Rubin, A | 1 |
Butt, WR; Franks, S; Horrocks, PM; London, DR; Lynch, SS | 1 |
Duvoisin, RC; Heikkila, RE; Manzino, L | 1 |
Gianutsos, G; Palmeri, JL | 1 |
Burke, JA; Chang, FW; Potter, DE | 1 |
Arnerić, SP; Chow, SA; Fischer, LJ; Long, JP | 1 |
Cook, DB; Hall, K; Johnston, DG; Kendall-Taylor, P; Patrick, D; Watson, M | 1 |
Beckman, J; Burton, K; Calne, DB; Martin, WR | 1 |
Blackwell, RE; Bradley, EL; Chang, RJ; DeVane, GW; Duvall, ER; Kline, LB; Vitek, JJ | 1 |
Calne, DB; Dambrosia, JM; Foster, N; Larsen, TA; LeWitt, PA; Newman, RP; Raphaelson, MI; Ward, CD | 1 |
Blackwell, RE; Bradley, EL; Rodgers-Neame, NT | 1 |
Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
Login, IS | 1 |
de Vries, JB; Feenstra, MG; Goedemoed, JH; Horn, AS; Rollema, H; Sumners, C | 1 |
Brincat, S; Lang, AE; Marsden, CD; Parkes, JD; Quinn, N | 1 |
Noonan, JJ; Rose, DP | 1 |
Ford, J; Jackson, JA; Jankovic, J | 1 |
Goldstein, M; Goodgold, A; Gopinathan, G; Leibowitz, M; Lieberman, AN; Neophytides, A; Pact, V; Walker, R | 1 |
Lang, AE; Marsden, CD; Parkes, JD; Quinn, NP; Toone, B | 1 |
Fuller, RW; Perry, KW | 1 |
Ahlenius, S; Engel, J; Larsson, K; Svensson, L | 1 |
Johnels, B | 1 |
Callaghan, JT; Crabtree, R; Lemberger, L | 1 |
Besser, GM; Delitala, G; Grossman, A; Hathway, NR; Yeo, T | 1 |
Agnati, LF; Andersson, K; Fuxe, K; Hökfelt, T; Köhler, C; Kuonen, D; Ogren, SO | 1 |
Eadie, MJ | 1 |
Bymaster, FP; Threlkeld, PG; Wong, DT | 1 |
Angeleri, V; Bonuccelli, U; Cossutta, E; De Mari, M; Foschi, N; Lamberti, P; Martignoni, E; Muratorio, A; Pacchetti, C; Pezzoli, G | 1 |
Mark, MH; Sage, JI | 1 |
Gsell, W; Lange, KW; Naumann, M; Oestreicher, E; Rausch, WD; Riederer, P | 1 |
Angeleri, VA; Bonuccelli, U; Cossutta, E; De Mari, M; Foschi, N; Lamberti, P; Martignoni, E; Muratorio, A; Pacchetti, C; Pezzoli, G | 1 |
Blackard, WG | 1 |
Comella, CL; Ristanovic, RK; Tanner, CM | 1 |
Sarapura, V; Schlaff, WD | 1 |
Clemens, JA; Okimura, T; Smalstig, EB | 1 |
Agid, Y; Bonnet, AM; Dubois, B; Marconi, R; Serre, I | 1 |
Angulo Cuesta, J; Guil Cid, M; Jiménez, FJ; López Alvarez, YJ; Sánchez-Chapado, M | 1 |
Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E | 1 |
Ahlskog, JE | 1 |
Jin, GZ; Wei, YF; Zhang, XX | 1 |
Canesi, M; Mariani, CB; Pesenti, A; Pezzoli, G | 1 |
Asanuma, M; Gómez-Vargas, M; Kohno, M; Nishibayashi, S; Ogawa, N | 1 |
Arai, N; Isaji, M; Itoh, F; Kojima, M; Miyagi, M; Taya, F; Ujiie, A | 1 |
Kuno, S | 1 |
Fici, GJ; Sethy, VH; VonVoigtlander, PF; Wu, H | 1 |
Wienkers, LC; Wynalda, MA | 1 |
Graham, JM; Grünewald, RA; Sagar, HJ | 1 |
de Yébenes, JG; García-Ruiz, PJ; Sánchez-Pernaute, R | 1 |
Müller, U; Pollmann, S; von Cramon, DY | 1 |
Conner, P; Fried, G | 1 |
Kuno, S; Mizuta, E; Yoshida, O; Yoshimura, N | 1 |
Amano, K; Takakura, K | 1 |
Allain, H; Bentué-Ferrer, D; Cardwell, GP; Hicks, CA; O'Neill, MJ; Reymann, JM; Ward, MA | 1 |
Geyer, MA; Oostwegel, JL; Randolph, E; Swerdlow, NR; Taaid, N | 1 |
Factor, SA | 1 |
Weiner, WJ | 1 |
Montastruc, JL; Rascol, O; Senard, JM | 1 |
Chuda, M; Hayabara, T; Ihara, Y; Kuroda, S | 1 |
Antonini, A; Barichella, M; Canesi, M; Mariani, CB; Pezzoli, G; Tesei, S; Zecchinelli, AL | 1 |
Ferreira, JJ; Galitzky, M; Montastruc, JL; Rascol, O | 1 |
Clarke C, E; Speller J, M | 1 |
Barbanoj, M; Casas, M; Jané, F; Prat, G; Robledo, P; Rubio, A | 1 |
Brannan, T; Prikhojan, A; Yahr, MD | 1 |
Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
Jankovic, J; Le, WD | 1 |
Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
Fukui, T; Hira, K; Shimbo, T; Takemura, M | 1 |
Hillman, R; Parvez, F; Pendleton, RG; Sayed, M | 1 |
Auerbach, PP; Cadenhead, K; Eastvold, A; Geyer, MA; Karban, B; Ploum, Y; Stephany, N; Swerdlow, NR | 1 |
Colao, A; di Sarno, A; di Somma, C; Lombardi, G; Pivonello, R | 1 |
Gekht, AB | 1 |
Kuhlmann, A; Müller, T; Reimer, J | 1 |
Bartholomeusz, CF; Box, G; Nathan, PJ; Van Rooy, C | 1 |
Fujinami, A; Kuno, S; Matsui, H; Mizuta, I; Ohta, K; Ohta, M | 1 |
Bankowski, BJ; Zacur, HA | 1 |
Ball, SG; Hall, K; James, RA; Kendall-Taylor, P; Pearce, SH; Quinton, R; Sibal, L; Ugwu, P | 1 |
Lang, AE; Razmy, A; Shapiro, CM | 1 |
Araki, I; Kuno, S; Mizuta, E; Yamasaki, S | 1 |
Hotta, M; Kamo, T; Kawakami, M; Nemoto, S; Oshima, J; Shimojo, S; Shiraishi, M; Sugihara, H; Takahashi, Y; Yasaki, S | 1 |
Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP | 1 |
Clarke, CE; Deane, KH; Spieker, S | 1 |
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P | 1 |
Hundemer, HP; Kolter, T; Roesch-Ely, D; Scheffel, H; Schwaninger, M; Weiland, S; Weisbrod, M | 1 |
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
Abs, R; Verhelst, J | 1 |
Molitch, ME | 1 |
Boulos, PT; Hamilton, DK; Laws, ER; Vance, ML | 1 |
Bonuccelli, U; Ceravolo, R; Del Dotto, P; Gambaccini, G; Logi, C; Lucetti, C; Murri, L; Rossi, G | 1 |
Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I | 1 |
Chung, EJ; Kim, JY; Lee, WY; Park, SW | 1 |
Croft, RJ; Galloway, M; Guille, V; Leung, S; Nathan, PJ; O'Neill, BV; Phan, KL | 1 |
Burger, E; Härtter, S; Kvernmo, T | 1 |
Al-Fulaij, MA; Beinborn, M; Kopin, AS; Ren, Y | 1 |
Hirohata, M; Ono, K; Yamada, M | 1 |
Baldeweg, T; Croft, RJ; Leung, S; Nathan, PJ | 1 |
Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K | 1 |
Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C | 1 |
Andersohn, F; Garbe, E | 1 |
Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H | 1 |
Pullan, PT | 1 |
Alkabbani, A; Doshi, K; Hamrahian, A; Hatipoglu, B; Kennedy, L; Makin, V; Mon, SY; Olansky, L; Thorton, JN; Weil, R | 1 |
Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
Andrews, KD; Flashman, LA; Ford, JC; Kenny, RM; McAllister, TW; McDonald, BC; Saykin, AJ | 1 |
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R | 1 |
Kasica, N; Mackiewicz, J; Osęka, M; Saładziak, K; Święch, A | 1 |
Chen, F; Chen, X; Wen, S; Zhang, Q; Zhou, C | 1 |
Reviews
38 review(s) available for bromocriptine and pergolide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
Topics: alpha-Synuclein; Amyloidogenic Proteins; Drug Discovery; Humans; Protein Aggregation, Pathological; Structure-Activity Relationship | 2019 |
Dopaminergic agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Dopamine Agents; Humans; Lactose; Lisuride; Methylcellulose; Oxazines; Parkinson Disease; Pergolide; Receptors, Dopamine | 1992 |
Novel approaches to the management of hyperprolactinemia.
Topics: Aminoquinolines; Bromocriptine; Dopamine Agents; Female; Humans; Hyperprolactinemia; Pergolide | 1991 |
[New anti-parkinsonian drugs].
Topics: Antiparkinson Agents; Bromocriptine; Humans; Lisuride; Parkinson Disease; Pergolide; Picolinic Acids; Selegiline | 1991 |
Dopaminergic agonists in the treatment of Parkinson's disease.
Topics: Bromocriptine; Dopamine Agents; Humans; Parkinson Disease; Pergolide | 1990 |
Medical treatment of pituitary adenomas: effects on tumor growth.
Topics: Adenoma; Adrenocorticotropic Hormone; Bromocriptine; Dihydroergotoxine; Dopamine; Drug Administration Schedule; Ergolines; Growth Hormone; Levodopa; Lisuride; Metergoline; Methysergide; Pergolide; Pituitary Neoplasms; Prolactin; Tomography, X-Ray Computed | 1985 |
Chronic pharmacological manipulation of dopamine receptors in brain.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Bromocriptine; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Pergolide; Receptors, Dopamine; Trifluoperazine | 1987 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome | 1988 |
Medical treatment of hyperprolactinaemic disorders.
Topics: Acromegaly; Bromocriptine; Delayed-Action Preparations; Dopamine; Ergolines; Female; Humans; Hyperprolactinemia; Lisuride; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Psychoses, Substance-Induced; Tamoxifen | 1986 |
Long-term use of dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Corpus Striatum; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pergolide; Receptors, Dopamine; Time Factors | 1985 |
Bromocriptine in Parkinson disease.
Topics: Aged; Animals; Bromocriptine; Drug Administration Schedule; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1985 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Neuroprotection by dopamine agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Bromocriptine; Dopamine Agonists; Humans; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Pergolide | 1994 |
Recent advances in the understanding of the pathophysiology and treatment of hyperprolactinemia.
Topics: Bromocriptine; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Pergolide; Prolactin; Receptors, Dopamine D2; Signal Transduction; Treatment Outcome | 1993 |
[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Retroperitoneal Fibrosis | 1995 |
Treatment of early Parkinson's disease: are complicated strategies justified?
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline | 1996 |
Pergolide mesylate in Parkinson's disease treatment.
Topics: Antiparkinson Agents; Bromocriptine; Controlled Clinical Trials as Topic; Dopamine Agonists; Humans; Lisuride; Neuroprotective Agents; Pergolide | 1995 |
[Treatment of Parkinson's disease with multiple drugs].
Topics: Amantadine; Bromocriptine; Cholinergic Antagonists; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide | 1997 |
Hyperprolactinemia; etiology, diagnosis and treatment alternatives.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pergolide; Prolactin; Receptors, Prolactin | 1998 |
Dopamine agonists.
Topics: Apomorphine; Benzothiazoles; Bromocriptine; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Receptors, Dopamine; Thiazoles; Treatment Outcome | 1999 |
The initial treatment of Parkinson's disease should begin with levodopa.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Drug Therapy, Combination; Essential Tremor; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine; Thiazoles; Time Factors | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pergolide | 2000 |
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Bromocriptine; Cell Culture Techniques; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Models, Animal; Neuroprotective Agents; Parkinson Disease; Pergolide; Pramipexole; Substantia Nigra; Thiazoles | 2001 |
Dopamine receptor agonists for treating prolactinomas.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Ergot Alkaloids; Female; Humans; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2002 |
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone | 2002 |
DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
Topics: Bromocriptine; Dopamine Agonists; Ergot Alkaloids; Humans; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic | 2002 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Bromocriptine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Pergolide; Tolcapone | 2004 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Hyperprolactinemia: pathophysiology and management.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estrogens; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Radiotherapy; Surgical Procedures, Operative | 2003 |
Pharmacologic resistance in prolactinoma patients.
Topics: Bromocriptine; Cabergoline; Cell Proliferation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Estrogens; Female; Humans; Male; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2 | 2005 |
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Topics: Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Heart Valve Diseases; Humans; Indoles; Pergolide; Pulmonary Fibrosis; Receptors, Dopamine | 2006 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2 | 2021 |
Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pergolide; Pramipexole | 2023 |
Trials
20 trial(s) available for bromocriptine and pergolide
Article | Year |
---|---|
A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Topics: Adult; Amenorrhea; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy; Female; Galactorrhea; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Radiography | 1991 |
Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia.
Topics: Adult; Blood Pressure; Bromocriptine; Dopamine Antagonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Luteinizing Hormone; Pergolide; Prolactin; Prospective Studies; Random Allocation; Time Factors | 1986 |
Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy
Topics: Adult; Aged; Aldosterone; Blood Pressure; Bromocriptine; Catecholamines; Dopamine; Female; Humans; Kidney; Male; Middle Aged; Norepinephrine; Pergolide; Pituitary Neoplasms; Prolactin; Renin; Stimulation, Chemical | 1988 |
Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide | 1988 |
Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study.
Topics: Adolescent; Adult; Aged; Amenorrhea; Bromocriptine; Clinical Trials as Topic; Dopamine; Ergolines; Female; Galactorrhea; Humans; Middle Aged; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Random Allocation | 1983 |
Comparison of pergolide and bromocriptine therapy in parkinsonism.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1983 |
Pergolide in late-stage Parkinson disease.
Topics: Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Sleep Wake Disorders | 1982 |
A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1995 |
Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infant; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pergolide; Single-Blind Method; Treatment Outcome | 1994 |
A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1995 |
D1- versus D2-receptor modulation of visuospatial working memory in humans.
Topics: Adult; Affect; Attention; Bromocriptine; Dopamine Agonists; Female; Humans; Male; Memory, Short-Term; Pergolide; Photic Stimulation; Prefrontal Cortex; Prolactin; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2; Space Perception | 1998 |
Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
Topics: Aged; Aged, 80 and over; Bromocriptine; Carbidopa; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Stereotaxic Techniques; Treatment Outcome | 1997 |
The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.
Topics: Adolescent; Adult; Bromocriptine; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Memory, Short-Term; Pergolide; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2003 |
Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Topics: Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Pergolide; Pituitary Function Tests; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyrotropin | 2002 |
Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Parkinson Disease; Pergolide; Prospective Studies; Treatment Outcome | 2004 |
Differential dopaminergic modulation of executive control in healthy subjects.
Topics: Adaptation, Psychological; Administration, Oral; Adult; Affect; Bromocriptine; Capsules; Cross-Over Studies; Domperidone; Double-Blind Method; Drug Administration Schedule; Feedback, Psychological; Functional Laterality; Hand; Humans; Male; Pergolide; Prefrontal Cortex; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Social Behavior | 2005 |
Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans.
Topics: Acoustic Stimulation; Adult; Bromocriptine; Dopamine Agonists; Double-Blind Method; Evoked Potentials, Auditory; Humans; Male; Pergolide; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Reference Values | 2006 |
Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects.
Topics: Acoustic Stimulation; Administration, Oral; Adult; Analysis of Variance; Bromocriptine; Contingent Negative Variation; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Electroencephalography; Evoked Potentials; Evoked Potentials, Auditory; Humans; Male; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2007 |
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
Other Studies
115 other study(ies) available for bromocriptine and pergolide
Article | Year |
---|---|
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Blotting, Northern; Brain; Cell Line; Cell Membrane; Cloning, Molecular; Dopamine; Humans; Kinetics; Molecular Sequence Data; Molecular Weight; Oligonucleotide Probes; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D5; RNA, Messenger; Sequence Homology, Nucleic Acid; Transfection | 1991 |
Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists.
Topics: Animals; Apomorphine; Cattle; Cerebral Cortex; Clonidine; Dopamine; Hydroxydopamines; Indicators and Reagents; Models, Molecular; Molecular Conformation; Motor Activity; Oxazines; Oxidopamine; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine; Rotation; Structure-Activity Relationship | 1984 |
Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity.
Topics: Animals; Apomorphine; Cattle; Cerebral Cortex; Chemical Phenomena; Chemistry; Dopamine; Isomerism; Oxazines; Receptors, Adrenergic, alpha | 1983 |
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Cell Line; Cell Membrane; Cloning, Molecular; Cyclic AMP; Gene Expression; Kidney Tubules, Proximal; Lysergic Acid Diethylamide; Molecular Sequence Data; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Radioligand Assay; Rats; Receptors, Serotonin; Recombinant Proteins; Serotonin; Transfection | 1993 |
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
Topics: Aminoquinolines; Animals; Dopamine Agonists; Imidazoles; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Methylamines; Mice; Microsomes, Liver; Molecular Structure; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Serotonin Receptor Agonists; Stereoisomerism | 1997 |
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
Topics: Alanine; Amino Acid Substitution; Animals; Bromocriptine; Combinatorial Chemistry Techniques; Dopamine Agonists; Models, Molecular; Pergolide; Point Mutation; Radioligand Assay; Rats; Receptors, Dopamine D2; Recombinant Proteins; Serine; Structure-Activity Relationship; Tumor Cells, Cultured | 2000 |
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Topics: Animals; Antiparkinson Agents; Binding Sites; Binding, Competitive; Cholinergic Antagonists; Cloning, Molecular; Cluster Analysis; Dopamine Agonists; Humans; Rats; Receptor, Muscarinic M1; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Neurotransmitter; Receptors, Serotonin | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
Topics: Ergolines; Humans; Ligands; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists | 2014 |
Behavioral characterization of the new potent nonselective dopamine agonist pergolide.
Topics: Analgesics; Animals; Avoidance Learning; Behavior, Animal; Body Temperature; Bromocriptine; Dogs; Female; Male; Mice; Motor Activity; Neuromuscular Junction; Oxotremorine; Pergolide; Postural Balance; Rats; Reserpine; Salivation; Seizures; Sleep; Time Factors | 1992 |
Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Diethylstilbestrol; Dose-Response Relationship, Drug; Ergolines; Female; Hyperplasia; Hyperprolactinemia; Pergolide; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Wistar; Receptors, Dopamine D2; Spiperone; Time Factors; Tritium | 1992 |
Malignant prolactinoma.
Topics: Bromocriptine; Combined Modality Therapy; Female; Humans; Middle Aged; Orbital Neoplasms; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma | 1992 |
General pharmacology of pergolide in animals. 1st communication: cardiovascular, respiratory and autonomic nervous system studies.
Topics: Acetylcholine; Administration, Oral; Anesthesia; Animals; Autonomic Nervous System; Bromocriptine; Carotid Arteries; Decerebrate State; Dogs; Female; Guinea Pigs; Hemodynamics; In Vitro Techniques; Male; Muscle, Smooth; Norepinephrine; Pergolide; Rats; Rats, Inbred Strains; Respiration; Vagus Nerve | 1992 |
The effect of mesulergine on prolactin secretion and anterior pituitary cells morphology in diethylstilboestrol-treated female Wistar rats.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Cell Division; Diethylstilbestrol; Drug Interactions; Ergolines; Female; Hyperprolactinemia; Immunohistochemistry; Pergolide; Pituitary Gland, Anterior; Prolactin; Rats | 1992 |
Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.
Topics: Adult; Brain Tissue Transplantation; Bromocriptine; Caudate Nucleus; Down-Regulation; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Quinuclidinyl Benzilate; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Neurotransmitter; Spiperone | 1991 |
Differential effects of dopamine agonists upon stimulated limbic and striatal dopamine release: in vivo voltammetric data.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Bromocriptine; Corpus Striatum; Dopamine; Dopamine Agents; Electrochemistry; Electrophysiology; Ergolines; In Vitro Techniques; Limbic System; Male; Microelectrodes; Nucleus Accumbens; Pergolide; Piperidines; Quinpirole; Rats; Rats, Inbred Strains; Stereotaxic Techniques | 1991 |
Pharmacological characterization of dopamine receptors in parasympathetic innervation of rat heart.
Topics: Acetylcholine; Animals; Apomorphine; Bradycardia; Bromocriptine; Decerebrate State; Dopamine Agents; Electric Stimulation; Ergolines; Heart; Heart Rate; Male; Pergolide; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Vagus Nerve | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Bromocriptine; Clonidine; Dopamine Agents; Ergolines; Female; Levodopa; Motor Activity; Pergolide; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Sulpiride | 1990 |
Prolactin reduction after combined therapy for prolactin macroadenomas.
Topics: Adenoma; Adult; Bromocriptine; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Libido; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Retrospective Studies | 1991 |
Effects of oral pergolide mesylate on nociceptive spinal cord reflexes in rats.
Topics: Animals; Bromocriptine; Dose-Response Relationship, Drug; Female; Haloperidol; Pain; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine; Reflex; Spinal Cord | 1991 |
Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs.
Topics: Adult; Bromocriptine; Female; Humans; Hyperprolactinemia; Lisuride; Magnetic Resonance Imaging; Male; Middle Aged; Pergolide; Prolactin; Tomography, X-Ray Computed | 1991 |
Effect of bromocriptine on neurogenic vasoconstriction in the isolated autoperfused hindquarters of the rat.
Topics: Animals; Apomorphine; Bromocriptine; Hindlimb; Male; Perfusion; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine; Sulpiride; Vasoconstriction | 1990 |
Early dopamine agonist therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Bromocriptine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Receptors, Dopamine | 1989 |
D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography.
Topics: Animals; Autoradiography; Behavior, Animal; Benzazepines; Brain; Bromocriptine; Deoxyglucose; Glucose; Male; Oxazines; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine; Salicylamides; Substantia Nigra | 1989 |
Agonist substitution in advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Drug Evaluation; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1989 |
Control of hyperprolactinemia with pergolide.
Topics: Bromocriptine; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Prolactin | 1986 |
The medical treatment of the hypersecreting pituitary gland.
Topics: Adenoma; Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Bromocriptine; Cyproheptadine; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Gland; Pituitary Neoplasms; Prolactin; Valproic Acid | 1985 |
Variability and selectivity of anterior pituitary response to dopamine agonists throughout the normal menstrual cycle.
Topics: Bromocriptine; Dopamine; Dopamine Antagonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menstrual Cycle; Pergolide; Pituitary Gland, Anterior; Pituitary Hormone-Releasing Hormones; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1986 |
Dopamine agonists as primary treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Long-Term Care; Parkinson Disease; Pergolide; Receptors, Dopamine | 1987 |
Natural and artificially induced ovulatory models related to lactation in the rat: role of prolactin.
Topics: Animals; Bromocriptine; Female; Follicle Stimulating Hormone; Lactation; Luteinizing Hormone; Models, Biological; Ovulation; Ovulation Induction; Pergolide; Postpartum Period; Pregnancy; Prolactin; Rats; Rats, Inbred Strains | 1988 |
Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat.
Topics: Animals; Apomorphine; Bromocriptine; Electroencephalography; Electromyography; Haloperidol; Male; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine; Sleep; Sleep, REM; Wakefulness | 1988 |
Effects of 8-OH-DPAT, lisuride and some ergot-related compounds on the acoustic startle response in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Bromocriptine; Ergolines; Lisuride; Male; Metergoline; Methiothepin; Naphthalenes; Pergolide; Quinpirole; Rats; Rats, Inbred Strains; Reflex, Startle; Tetrahydronaphthalenes | 1985 |
International symposium on early dopamine agonist therapy of Parkinson's disease.
Topics: Animals; Bromocriptine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease; Pergolide; Time Factors | 1988 |
Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
Topics: Adult; Bromocriptine; Carbidopa; Dystonia; Ergolines; Humans; Levodopa; Meige Syndrome; Middle Aged; Parkinson Disease; Pergolide; Torticollis | 1986 |
Discordant responses of prolactinoma to two different dopamine agonists.
Topics: Adult; Bromocriptine; Drug Resistance; Ergolines; Female; Humans; Pergolide; Pituitary Neoplasms; Prolactin; Tomography, X-Ray Computed | 1986 |
Dopamine agonists for reducing depression associated with hyperprolactinemia.
Topics: Analysis of Variance; Bromocriptine; Depression; Depressive Disorder; Drug Evaluation; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Prolactin | 1986 |
Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.
Topics: Animals; Basal Ganglia; Bromocriptine; Carbidopa; Dopamine; Dopamine Antagonists; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Male; Neurotensin; Pergolide; Rats; Rats, Inbred Strains; Trifluoperazine | 1986 |
Behavioral effects of long-term neuroleptic treatment in Cebus monkeys.
Topics: Animals; Apomorphine; Behavior, Animal; Bromocriptine; Cebus; Dextroamphetamine; Dopamine; Ergolines; Haloperidol; Humans; Mastication; Pergolide; Receptors, Dopamine; Stereotyped Behavior | 1985 |
Management of prolactinomas. A reappraisal.
Topics: Adenoma; Bromocriptine; Ergolines; Female; Humans; Lisuride; Metergoline; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Radiotherapy Dosage; Radiotherapy, High-Energy; Time Factors | 1985 |
[Dopaminergic agonists in Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Piribedil | 1986 |
Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases.
Topics: Biological Assay; Brain Neoplasms; Bromocriptine; Combined Modality Therapy; Ergolines; Female; Histocytochemistry; Hormones; Humans; Microscopy, Electron; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pergolide; Pituitary Neoplasms; Prolactin | 1985 |
Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Outcome and Process Assessment, Health Care; Parkinson Disease; Pergolide; Time Factors | 1985 |
The effect of dopamine agonist therapy on large functionless pituitary tumours.
Topics: Adenoma, Chromophobe; Adult; Bromocriptine; Dopamine; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prospective Studies | 1985 |
Dopamine agonists in hyperprolactinemia.
Topics: Bromocriptine; Ergolines; Humans; Hyperprolactinemia; Pergolide | 1985 |
Dopamine agonists and Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Brain; Bromocriptine; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Neurons; Parkinson Disease; Pergolide; Piribedil; Receptors, Dopamine | 1984 |
Physiologic disposition of pergolide.
Topics: Adult; Animals; Bromocriptine; Chromatography, High Pressure Liquid; Ergolines; Feces; Humans; Male; Middle Aged; Pergolide | 1981 |
Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment.
Topics: Administration, Oral; Adult; Bromocriptine; Depression, Chemical; Ergolines; Female; Follicle Stimulating Hormone; Growth Hormone; Humans; Luteinizing Hormone; Male; Pergolide; Prolactin; Time Factors | 1981 |
Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway.
Topics: Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Ergolines; Female; Hydroxydopamines; Oxidopamine; Parkinson Disease; Pergolide; Rats; Rats, Inbred Strains | 1982 |
Effects of three dopamine agonists on cage climbing behavior.
Topics: Animals; Behavior, Animal; Bromocriptine; Ergolines; Male; Mice; Mice, Inbred Strains; Motor Activity; Pergolide | 1983 |
Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment.
Topics: Administration, Topical; Animals; Bromocriptine; Domperidone; Ergolines; Eye; Ganglia, Sympathetic; Intraocular Pressure; Male; Pergolide; Rabbits; Sympathectomy | 1984 |
Dopamine analog-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas.
Topics: Adrenal Medulla; Animals; Apomorphine; Blood Glucose; Bromocriptine; Dextroamphetamine; Dihydroxyphenylalanine; Dopamine; Ergolines; Indans; Insulin; Islets of Langerhans; Male; Pergolide; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Dopamine; Tetrahydronaphthalenes | 1984 |
Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
Topics: Adult; Aged; Bromocriptine; Dopamine; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Function Tests; Pituitary Neoplasms; Pregnancy; Prolactin; Sella Turcica; Tomography, X-Ray Computed | 1984 |
Dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1984 |
Long-term monolayer culture of human anterior pituitary cells: functional validation of a method.
Topics: Bromocriptine; Cells, Cultured; Ergolines; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Methods; Pergolide; Pituitary Gland, Anterior; Prolactin; Thyrotropin-Releasing Hormone; Time Factors | 1984 |
Pergolide versus bromocriptine.
Topics: Bromocriptine; Ergolines; Humans; Parkinson Disease; Pergolide | 1984 |
A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Butyrolactone; Animals; Behavior, Animal; Bromocriptine; Dopamine; Ergolines; Homovanillic Acid; Models, Neurological; Motor Activity; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1983 |
Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Bromocriptine; Ergolines; Female; Growth Hormone; Hypophysectomy; Male; Mammary Neoplasms, Experimental; Methylnitrosourea; Nitrosourea Compounds; Pergolide; Prolactin; Rats | 1982 |
Progressive supranuclear palsy: clinical features and response to treatment in 16 patients.
Topics: Aged; Bromocriptine; Bulbar Palsy, Progressive; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Pergolide | 1983 |
Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Disability Evaluation; Drug Evaluation; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1983 |
Dopa dose-dependent sexual deviation.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Ergolines; Humans; Male; Middle Aged; Paraphilic Disorders; Parkinson Disease; Pergolide | 1983 |
Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats.
Topics: 4-Butyrolactone; Animals; Brain Chemistry; Bromocriptine; Dopamine; Ergolines; Furans; Haloperidol; Pergolide; Rats; Rats, Inbred Strains | 1982 |
Effects of pergolide and bromocriptine on male rat sexual behavior.
Topics: Animals; Bromocriptine; Ergolines; Male; Pergolide; Rats; Sexual Behavior, Animal | 1982 |
Locomotor hypokinesia in the reserpine-treated rat: drug effects from the corpus striatum and nucleus accumbens.
Topics: Animals; Antiparkinson Agents; Apomorphine; Bromocriptine; Corpus Striatum; Ergolines; Locomotion; Male; Motor Activity; Nucleus Accumbens; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine; Reserpine; Septal Nuclei | 1982 |
Pergolide, a potent long-acting dopamine-receptor agonist.
Topics: Adult; Blood Pressure; Bromocriptine; Circadian Rhythm; Dose-Response Relationship, Drug; Ergolines; Ergot Alkaloids; Growth Hormone; Hormones; Humans; Male; Middle Aged; Myocardial Contraction; Pergolide; Perphenazine; Prolactin; Receptors, Dopamine; Time Factors | 1980 |
Two new dopamine agonists that are long acting in vivo but short acting in vitro.
Topics: Animals; Bromocriptine; Dose-Response Relationship, Drug; Ergolines; In Vitro Techniques; Male; Pergolide; Prolactin; Rats; Secretory Rate; Time Factors | 1980 |
Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain; Bromocriptine; Caudate Nucleus; Corpus Striatum; Ergolines; Kinetics; Organ Specificity; Pergolide; Putamen; Rats; Receptors, Dopamine | 1981 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Pergolide; Prognosis; Selegiline | 1995 |
Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Binding, Competitive; Brain Chemistry; Bromocriptine; Cattle; Corpus Striatum; Dopamine; Hippocampus; Homovanillic Acid; Hydroxyindoleacetic Acid; In Vitro Techniques; Membranes; Pergolide; Radioligand Assay; Receptors, Dopamine; Receptors, Dopamine D2 | 1993 |
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating | 1995 |
Edema--an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs.
Topics: Aminoquinolines; Bromocriptine; Dopamine Agents; Edema; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactinoma | 1993 |
Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.
Topics: Aged; Bromocriptine; Carbidopa; Hallucinations; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Sleep; Sleep, REM | 1993 |
Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
Topics: Administration, Oral; Animals; Bromocriptine; Corpus Striatum; Injections, Intraperitoneal; Male; Oxidopamine; Pergolide; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reserpine; Stereotyped Behavior; Substantia Nigra | 1993 |
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide | 1995 |
Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area.
Topics: Animals; Bromocriptine; Dopamine Agonists; Electrophysiology; Male; Neurons; Pergolide; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra | 1995 |
Scavenging effects of dopamine agonists on nitric oxide radicals.
Topics: Benzoates; Bromocriptine; Dopamine Agonists; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Free Radicals; Imidazoles; Kinetics; Nitric Oxide; Pergolide; Spin Labels | 1996 |
Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
Topics: Animals; Benzazepines; Binding, Competitive; Bromocriptine; Cabergoline; Dopamine Agonists; Dopamine Antagonists; Ergolines; In Vitro Techniques; Male; Pergolide; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior | 1996 |
D1 dopamine receptor activity of anti-parkinsonian drugs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Benzothiazoles; Bromocriptine; Cells, Cultured; Cerebellum; Clozapine; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiazoles | 1997 |
Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.
Topics: Benzothiazoles; Bromocriptine; Cytochrome P-450 Enzyme Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Pergolide; Pramipexole; Thiazoles | 1997 |
Hallucinosis in idiopathic Parkinson's disease.
Topics: Aged; Bromocriptine; Cognition Disorders; Depressive Disorder; Dopamine Agonists; Female; Hallucinations; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Psychomotor Disorders; Retrospective Studies; Severity of Illness Index; Time Factors | 1997 |
[A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Pergolide; Retrospective Studies; Tremor | 1997 |
Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Topics: Animals; Bromocriptine; Dopamine Agonists; Ergolines; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Reflex; Triazoles; Urinary Bladder; Urination | 1998 |
Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Brain Ischemia; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Gerbillinae; Haloperidol; Hippocampus; Lisuride; Neuroprotective Agents; Pergolide; Receptors, Dopamine D2 | 1998 |
Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats.
Topics: Acoustic Stimulation; Amantadine; Animals; Bromocriptine; Dopamine Agents; Dopamine Agonists; Drug Interactions; Humans; Indoles; Male; Pergolide; Rats; Rats, Sprague-Dawley; Reflex, Startle; Species Specificity | 1998 |
Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Erythrocytes; Humans; Hydroxyl Radical; Levodopa; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pergolide; Severity of Illness Index; Statistics as Topic; Superoxide Dismutase; Time Factors | 1999 |
An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Bromocriptine; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Therapeutic Equivalency | 1999 |
Sleep attacks and Parkinson's disease treatment.
Topics: Accidents, Traffic; Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Female; Humans; Lisuride; Male; Middle Aged; Narcolepsy; Parkinson Disease; Pergolide; Piribedil | 2000 |
Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
Topics: Animals; Bromocriptine; Caffeine; Denervation; Drug Administration Schedule; Drug Combinations; Drug Tolerance; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Rats; Rats, Sprague-Dawley; Rotation | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
Pergolide and Parkinson's disease: new preparation. No clear benefit.
Topics: Antiparkinson Agents; Bromocriptine; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Treatment Outcome | 2000 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.
Topics: Aged; Bromocriptine; Cost-Benefit Analysis; Dopamine Agonists; Female; Hospitalization; Humans; Japan; Male; Markov Chains; Middle Aged; Parkinson Disease; Pergolide; Quality-Adjusted Life Years | 2001 |
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Bromocriptine; Disease Models, Animal; Drosophila melanogaster; Genotype; Levodopa; Motor Activity; Nerve Tissue Proteins; Neurons; Parkinson Disease; Pergolide; Postural Balance; Synapses; Synucleins | 2002 |
Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.
Topics: Adolescent; Adult; Amantadine; Amphetamine; Analysis of Variance; Blood Pressure; Bromocriptine; Dopamine Agonists; Double-Blind Method; Heart Rate; Humans; Male; Pergolide; Psychomotor Performance; Reflex, Startle; Time Factors | 2002 |
Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide.
Topics: Bromocriptine; Dopamine Agonists; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Pergolide | 2002 |
Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Astrocytes; Blotting, Northern; Brain-Derived Neurotrophic Factor; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Ergolines; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred ICR; Nerve Growth Factor; Nerve Growth Factors; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2003 |
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Topics: Aged; Benzothiazoles; Bromocriptine; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationship, Drug; Ergot Alkaloids; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Polysomnography; Pramipexole; Prospective Studies; Sleep; Thiazoles; Wakefulness | 2004 |
Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients.
Topics: Aged; Bromocriptine; Female; Humans; Middle Aged; Parkinson Disease; Patient Selection; Pergolide; Urination Disorders | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Cardiopulmonary complications of ergot-derivative dopamine agonists.
Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone | 2004 |
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide | 2004 |
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Outcome | 2005 |
Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System; Bromocriptine; Disability Evaluation; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Pergolide; Prognosis; Survival Analysis | 2006 |
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2006 |
Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Dopamine Agonists; Echocardiography; Ergot Alkaloids; Heart Valve Diseases; Humans; Middle Aged; Parkinson Disease; Pergolide; Reference Values | 2006 |
Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
Topics: Amino Acid Sequence; Amino Acid Substitution; Amino Acids; Animals; Binding Sites; Bromocriptine; Cell Line, Tumor; Dopamine Agonists; Drosophila; Humans; Indoles; Ligands; Luciferases; Molecular Sequence Data; Mutation; Pergolide; Piribedil; Receptors, Dopamine D2; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Transfection | 2007 |
Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
Topics: alpha-Synuclein; Antiparkinson Agents; Bromocriptine; Dopamine; Dose-Response Relationship, Drug; In Vitro Techniques; Molecular Structure; Neurofibrillary Tangles; Pergolide; Polymers; Selegiline; Trihexyphenidyl | 2007 |
The frequency of cardiac valvular regurgitation in Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence | 2008 |
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors | 2009 |
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States | 2009 |
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography | 2009 |
Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Thromboembolism; Young Adult | 2013 |
Differential Effects of Pergolide and Bromocriptine on Working Memory Performance and Brain Activation after Mild Traumatic Brain Injury.
Topics: Adolescent; Adult; Brain; Brain Concussion; Bromocriptine; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Pergolide; Young Adult | 2021 |
The Inhibitory Effect of Selected D
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Bromocriptine; Cabergoline; Dopamine Agonists; Hypoxia; Larva; Neovascularization, Pathologic; Pergolide; Vascular Endothelial Growth Factor A; Zebrafish | 2022 |